There were ~2,500 in 2022, 4,700 in 2023, 8,500 in 2024 and 10,745 through September 2025
Blood sugar stabilization GLP-1 Agonist boosts insulin production which helps stabilize blood sugar
During this process, the body destroys fat cells outright and permanentlya welcome side effect to the muscle-building process
In the MD Anderson cohort, semaglutide and tirzepatide users had a median weight change of -2.6% at 12 months, smaller than the figures typically seen in general obesity trials

Contact your GP or call NHS 111 if you experience: Persistent or worsening nausea, vomiting, or abdominal pain Rapid or irregular heartbeat (palpitations) Injection site reactions, including redness, warmth, swelling, or discharge Symptoms of hypoglycaemia (low blood sugar), particularly if taking other glucose-lowering medicines concurrently Any change in vision, particularly if you have diabetes seek a GP referral for optometry or ophthalmology review promptly Unexplained changes in mood Call 999 or attend your nearest A&E immediately if you experience: Signs of a severe allergic reaction (anaphylaxis), including swelling of the face, lips, or throat, difficulty breathing, or collapse Severe abdominal pain with systemic symptoms such as fever or rapid deterioration, which may indicate pancreatitis or another serious complication Severe chest pain If you are a clinical trial participant , contact your research site or trial team immediately for any adverse event or safety concern do not wait for a routine appointment

Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar